1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Sjogren's Syndrome - Pipeline Review, H2 2014

Sjogren's Syndrome - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 55 pages

Sjogren's Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Sjogren's Syndrome - Pipeline Review, H2 2014’, provides an overview of the Sjogren's Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sjogren's Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Sjogren's Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sjogren's Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Sjogren's Syndrome - Pipeline Review, H2 2014
Table of Contents
Introduction 6
Global Markets Direct Report Coverage 6
Sjogren's Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Sjogren's Syndrome - Overview 8
Pipeline Products for Sjogren's Syndrome - Comparative Analysis 9
Sjogren's Syndrome - Therapeutics under Development by Companies 10
Sjogren's Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Sjogren's Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Sjogren's Syndrome - Products under Development by Companies 15
Sjogren's Syndrome - Products under Investigation by Universities/Institutes 16
Sjogren's Syndrome - Companies Involved in Therapeutics Development 17
Bristol-Myers Squibb Company 17
MedImmune, LLC 18
Novartis AG 19
Takeda Pharmaceutical Company Limited 20
Toleranzia AB 21
Sjogren's Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
abatacept (recombinant) - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
ABS-11 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CFZ-533 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
IMSO-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
MEDI-4920 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
MLN-3126 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
NS2 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Recombinant Protein for Sjogren's Syndrome - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
VAY-736 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Sjogren's Syndrome - Recent Pipeline Updates 46
Sjogren's Syndrome - Dormant Projects 50
Sjogren's Syndrome - Discontinued Products 51
Sjogren's Syndrome - Product Development Milestones 52
Featured News and Press Releases 52
Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma and Immunology Annual Meeting 52
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables

Number of Products under Development for Sjogren's Syndrome, H2 2014 8
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
umber of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Sjogren's Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2014 17
Sjogren's Syndrome - Pipeline by MedImmune, LLC, H2 2014 18
Sjogren's Syndrome - Pipeline by Novartis AG, H2 2014 19
Sjogren's Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20
Sjogren's Syndrome - Pipeline by Toleranzia AB, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Sjogren's Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 46
Sjogren's Syndrome - Dormant Projects, H2 2014 50
Sjogren's Syndrome - Discontinued Products, H2 2014 51

List of Figures

Number of Products under Development for Sjogren's Syndrome, H2 2014 8
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 23
Number of Products by Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Top 10 Routes of Administration, H2 2014 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 27
Number of Products by Top 10 Molecule Types, H2 2014 29
Number of Products by Stage and Top 10 Molecule Types, H2 2014 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.